3 documents found, page 1 of 1
Consistent trajectories of rhinitis control and treatment in 16,177 weeks
Sousa-Pinto, Bernardo; Schünemann, Holger J.; Sá-Sousa, Ana; Vieira, Rafael José; Amaral, Rita; Anto, Josep M.; Klimek, Ludger; Czarlewski, WienczyslawaFunding Information: MASK‐air® has been supported by EU grants (POLLAR, EIT Health; Structural and Development Funds, Twinning, EIP on AHA and H2020) and educational grants from Mylan‐Viatris, ALK, GSK, Novartis and Uriach. Publisher Copyright: © 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.; Introduction: Data from mHealth apps can provide...
Allergen immunotherapy in MASK-air users in real-life
Sousa-Pinto, Bernardo; Azevedo, Luís Filipe; Sá-Sousa, Ana; Vieira, Rafael José; Amaral, Rita; Klimek, Ludger; Czarlewski, Wienczyslawa; Anto, Josep M.Funding Information: MASK-air has been supported by Charit? Universit?tsmedizin Berlin, EU Grants (EU Structural and Development Funds, POLLAR: EIT Health POLLAR, EIT Health Twinning) and educational grants from Mylan-Viatris, ALK, GSK, Novartis and Uriach. Open access funding enabled and organized by Projekt DEAL. Publisher Copyright: © 2022 The Authors. Clinical and Translational Allergy published by John Wil...
Comparison of rhinitis treatments using MASK-air® data and considering the mini...
Sousa-Pinto, Bernardo; Schünemann, Holger J.; Sá-Sousa, Ana; Vieira, Rafael José; Amaral, Rita; Anto, Josep M.; Klimek, Ludger; Czarlewski, WienczyslawaFunding Information: IA reports personal fees from Roxall, Menarini, UCB, Faes Farma, Sanofi, Bial, Amgen, Abbott, Bayer, Organon. SBA reports grants from TEVA, personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, Mylan. JB reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, personal fees from...